SFV vectors encoding these nanobody-Fc fusion proteins showed potent antitumor activity in mouse models of CRC and melanoma, outperforming control vectors encoding conventional antibodies against PD-1 and PD-L1 [136]. Here, CD274 is linked to melanoma.